Idiopathic pulmonary fibrosis: Recent milestones in disease management

European Respiratory Review

Volumn 21, Issue 124, 2012, Pages 140-

  Costabel, Ulrich ^a  

^a RUHRLANDKLINIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE;

DISEASE SEVERITY; EDITORIAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; PATHOGENESIS; PRACTICE GUIDELINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MANAGEMENT; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES;

EID: 84861861648     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00000712     Document Type: Editorial

References (6)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. American Cancer Society. Cancer Facts and Figures 2009. www.cancer. org/Research/CancerFactsFigures/CancerFactsFigures/cancer-factsfigures-2009
3. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146.
4. Richeldi L. Assessing the treatment effect from multiple trials in idiophathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147-151.
5. Günther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 152-159.
6. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 160-166.